

Japan Biotech Forum: London 2010

- 09:30 Registration with tea and coffee
- 10:00 **Welcome** Dr Chizuko Koseki, Representative Director, transB Ltd.
- 10:05 **Overview of the current Japanese biotech industry and outlook**
Mr Setsuo Morishita, Deputy Director, Strategic Planning, Japan Bioindustry Association (JBA)
- 10:15 **Insight into investment strategies adopted by a Japanese pharma company**
Dr Noriyuki Matsuo, Manager, Apposite Capital and Dainippon Sumitomo Pharma Europe
- 10:25 **Presentations from invited Japanese biotech companies (see overleaf)**
- 12:30 Lunch
- 13:30 **Presentations and panel discussion on licensing and investment strategies**
Dr Takashi Ono, Vice President, Solasia Pharma
Mr Koji Abe, General Manager, ITOCHU Corporation
Ms Tomomi Okamoto, Advisor, Red Abbey Venture Partners
- 14:20 **Summary remarks** Dr Chris Redhead, Senior Advisor, transB Ltd.
- 14:30 **One-to-one partnering with selected companies**
- 16:30 Close

Sponsors and supporters



THOMSON REUTERS



Thursday 9 September 2010, The Royal Society, London

www.transb.co.uk/japan_biotech_forum_2010.htm

Cherry-picked biotech companies from Japan

transB is bringing a handful of innovative Japanese biotech companies to present at this Forum. Products and technologies listed here are a partial list from their portfolio and more products may be presented.

CanBas *Dr Takumi Kawabe, President and CEO*

Clinical stage biopharmaceutical company (MOTHERS index: 4575)

CBP501: Peptide therapeutic for cancer; Phase II (malignant pleural mesothelioma and non-small-cell lung cancer)

CBS9106: Oral small molecule therapeutic for cancer; Preclinical

LivTech *Dr Koji Nakamura, CEO*

Biotech company developing anti-cancer therapeutic antibodies based on tissue stem cells

LIV-2008: Monoclonal antibody for pancreatic cancer; Preclinical

REGiMMUNE *Mr Haru Morita, President and CEO*

Biotech company developing immune-regulating therapeutics

RGI-2001: Novel therapeutic for graft versus host disease (GvHD); Preclinical

RGI-1001: Novel therapeutic for cedar allergy; Preclinical

RGI-3010: Immune-tolerance inducing liposome encapsulating proinsulin for type I diabetes; Preclinical

Chiome Bioscience *Mr Masa Fujiwara, CEO*

Biotech company with proprietary technology in monoclonal antibodies

ADLib® system: Proprietary technology for fast generation of monoclonal antibodies against tough antigens

D. Western Therapeutics Institute (DWTI) *Mr Yuichi Hidaka, President & CEO*

Clinical stage biopharmaceutical company with proprietary protein kinase inhibitors (MOTHERS index: 4576)

HMN-214: Anti-cancer agent with novel MoA; Phase I completed in US

Various NCEs for glaucoma, cancer, anti-thrombotic; Preclinical

Please note: this list of speakers is subject to change, and other companies may be invited to speak.

Benefits of attending

- Presentations from emerging Japanese biotech companies
- Corporate and product analyses provided as handouts
- One-to-one partnering opportunity
- Networking with delegates from the licensing and investment communities

Registration

Standard delegate rate: £250 + VAT

Additional delegate(s) from the same company: £200 + VAT

Please note: Attendance will be confirmed upon receipt of payment. Prices include all refreshments and delegate documentation.

Attendance is by INVITATION ONLY to ensure that the quality of interactions is maintained. To apply for an invitation or to register, please contact Maki Aoyama at m.aoyama@transb.co.uk. Cancellations must be made at least 7 days prior to the event for refunds to be made (minus a 10% administration charge). No refunds will be made after 3 September.

Delegate profile

The Forum will have an intimate and semi-closed atmosphere with around 100 targeted delegates from the licensing and business development functions of pharmaceutical and venture capital companies. Delegates from last year's forum include companies such as:

| | | | |
|--------------------------------|------------------------|---------------------|----------------------|
| aRigen Pharmaceuticals | Astellas Pharma Europe | BTG | Circassia |
| Coller Capital | Cytos | e-Therapeutics | GE Healthcare |
| GlaxoSmithKline | Kyowa Hakko Kirin UK | Lectus Therapeutics | MebioPharm |
| Menarini Biotech | Mitsubishi Tanabe | Mitsui & Co Europe | Ono Pharma UK |
| Orion Corporation | Pfizer | RaQualia | ReproCELL |
| Sinclair Pharma | Sosei Group | Stiefel (GSK) | Teijin Pharma |
| Vaccine Research International | Vectura Group | Xention | Zeria Pharmaceutical |

A consulting firm with a focus on the Japanese biotech and pharmaceutical sectors

transB's vision is to provide clients with the best insights and analyses of cutting edge science, products and business opportunities to enable informed decisions that lead to successful cross-border transactions. The role of transB is to act as a powerful catalyst that bridges the gap between Japanese biotech communities and the global stage. For more information, contact Chizuko Koseki at c.koseki@transb.co.uk.